Of the 176 participants, 110 (62.5%) were affected by HR+/HER2- tumours, 48 (27.3%) by TNBCs, 13 (7.4%) by HER2+ tumours, including nine HR+/HER2+ (5.1%) and four by HER2-enriched (HR-/HER2+) (2.3%) lesions (Table 1). This evidence concerns the gene HR and neoplasm.